AAM Backs FDA’s Proposal For Skinny-Label Safe Harbors
While US Senate Judiciary Committee Holds Hearing On Drug Pricing And Bills
Executive Summary
AAM expressed its support for the FDA’s attempt to protect generics and biosimilar companies and their products with skinny labels that carve out patented indications. Meanwhile, the Senate Committee’s hearing on drug pricing gets mixed opinions.